Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Purging with 4-hydroperoxycyclophosphamide.

R J Jones1

  • 1Johns Hopkins Oncology Center, Baltimore, MD 21287-8967.

Journal of Hematotherapy
|January 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fracture-related hospitalisations in newly diagnosed high-risk localised or metastatic hormone-sensitive prostate cancer: secondary analysis of the STAMPEDE phase III trials of docetaxel and zoledronic acid using healthcare systems data.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Cancer Trial Impact: Understanding Implementation of the Short Course Oncology Treatment (SCOT) Trial Findings in colorectal cancer at a National Level.

Clinical oncology (Royal College of Radiologists (Great Britain))·2022
Same author

Using diffusion MRI data acquired with ultra-high gradient strength to improve tractography in routine-quality data.

NeuroImage·2021
Same author

Fermentative volatile fatty acid production and recovery from grass using a novel combination of solids separation, pervaporation, and electrodialysis technologies.

Bioresource technology·2021
Same author

Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: Ann Oncol 2019; 30: 1992-2003.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2019
Same journal

Comparative evaluation of procedures with a Baxter CS-3000 cell separator for collecting peripheral blood cells from children.

Journal of hematotherapy·1999
Same journal

Graft engineering of G-CSF-mobilized allogeneic leukapheresis products by counterflow centrifugal elutriation after CD34 column adsorption.

Journal of hematotherapy·1999
Same journal

Serum granulocyte colony-stimulating factor kinetics in children receiving intense chemotherapy with or without stem cell support.

Journal of hematotherapy·1999
Same journal

Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92.

Journal of hematotherapy·1999
Same journal

The differentiating effect of retinoic acid and vincristine on acute myeloid leukemia.

Journal of hematotherapy·1999
Same journal

Comparison of T-cell-depleted BMT and PBPCT with respect to chimerism, graft rejection, and leukemic relapse.

Journal of hematotherapy·1999
See all related articles

High-dose chemotherapy with autologous bone marrow transplantation (BMT) is effective for leukemia and lymphoma. Purging the marrow with 4-hydroperoxycyclophosphamide (4-HC) aims to prevent relapse by removing tumor cells.

Area of Science:

  • Hematology
  • Oncology
  • Transplantation Medicine

Background:

  • Autologous bone marrow transplantation (BMT) following high-dose chemotherapy is a standard treatment for lymphomas and acute leukemias.
  • A significant challenge in BMT is the potential for relapse due to the infusion of residual tumor cells within the harvested autologous marrow.
  • In vitro purging techniques have been developed to eliminate these contaminating tumor cells from the BMT graft.

Purpose of the Study:

  • To review the development and application of 4-hydroperoxycyclophosphamide (4-HC) as a cytotoxic purging agent for autologous bone marrow grafts.
  • To discuss the role of purging in reducing relapse rates in patients undergoing BMT for hematologic malignancies.

Main Methods:

  • Review of studies and clinical experience with 4-hydroperoxycyclophosphamide (4-HC) and mafosfamide as cytotoxic purging agents.

Related Experiment Videos

  • Focus on the historical development and widespread use of 4-HC in autologous BMT procedures.
  • Examination of the rationale and techniques employed for ex vivo purging of bone marrow grafts.

    • Main Results:

    • 4-hydroperoxycyclophosphamide (4-HC) has become a widely used agent for purging autologous bone marrow grafts.
    • Over 700 patients have received 4-HC-purged autologous bone marrow transplants at Johns Hopkins since 1980.
    • Cytotoxic purging agents, particularly cyclophosphamide congeners like 4-HC, are frequently employed despite ongoing debate about their necessity and efficacy.

    Conclusions:

    • 4-hydroperoxycyclophosphamide (4-HC) has played a significant role in the evolution of purging strategies for autologous bone marrow transplantation.
    • The continued use of 4-HC highlights its perceived importance in improving outcomes for patients with acute leukemia and lymphoma.
    • Further research may be needed to definitively establish the efficacy and necessity of purging in allogeneic BMT contexts.